Verona’s RPL554 improves lung function in CF trial
London, UK-based Verona Pharma’s experimental phosphodiesterase therapy has hit targets in a mid-stage trial in patients with cystic fibrosis.
Read More
Tag: COPS
- Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
- Lebrikizumab shows strong results for children with atopic dermatitis
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
